Fluicell AB (5J90) AI Stock Analysis

3 Followers

Fluicell AB

(Frankfurt:5J90)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue and Profitability InflectionThe strong TTM revenue increase alongside positive EBIT and net income marks a meaningful operating inflection. If growth continues, expanding revenue can improve fixed-cost absorption and provide a more durable earnings base than the company’s prior loss-making periods.

Negative Factors

Negative Cash GenerationThe company is not yet self-funding despite reporting positive net income. Negative operating cash flow and materially negative free cash flow can require continued financing, limiting flexibility and making execution of growth plans more dependent on external capital.

Fluicell AB (5J90) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 3.42M
Dividend Yield: ―
Average Volume (3M): 670
Price to Earnings (P/E): 14.0
Beta (1Y): -0.65
Revenue Growth: 872.34%
EPS Growth: ―
Country: Germany
Employees: 11
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Fluicell AB Business Overview & Revenue Model

Company Description

Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic sys...

Fluicell AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:5J90 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:NXTCL	46Neutral	SEK 32.36M	-0.65	-81.23%	―	-4.02%	35.86%
SE:XINT	46Neutral	SEK 120.58M	-2.39	245.07%	―	-38.46%	9.02%
SE:BIOVIC.B	41Neutral	SEK 89.52M	-1.30	-75.51%	―	56.06%	63.95%
SE:FLUO	40Underperform	SEK 480.67M	-6.51	―	―	―	-23.57%

* Healthcare Sector Average

Performance Comparison

DE:5J90 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:5J90	Fluicell AB	2.44	1.30	114.04%
SE:XINT	Xintela AB	0.14	-0.12	-46.77%
SE:BIOVIC.B	Biovica International AB Class B	0.32	-0.25	-43.36%
SE:NXTCL	NextCell Pharma AB	0.25	-0.55	-68.88%
SE:BIOWKS	Bio-Works Technologies AB	3.02	0.27	9.82%
SE:FLUO	FluoGuide A/S	28.90	-14.80	-33.87%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Fluicell AB AI Stock Analysis